Mal-PEG2-VCP-Eribulin

Modify Date: 2024-01-04 16:00:46

Mal-PEG2-VCP-Eribulin structure	Common Name	Mal-PEG2-VCP-Eribulin
	CAS Number	2130869-18-8	Molecular Weight	1374.57
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₇₀H₉₉N₇O₂₁	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Mal-PEG2-VCP-Eribulin

Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].

Name	Mal-PEG2-VCP-Eribulin

Description	Mal-PEG2-VCP-Eribulin consists the ADCs linker (Mal-PEG2-VCP) and Eribulin[1]. Eribulin is a mechanistically unique microtubule inhibitor for cancer[2]. Mal-PEG2-VCP-Eribulin is an Eribulin-based drug for antibody conjugates[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Antibody-drug Conjugate >> Drug-Linker Conjugates for ADC
References	[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1. [2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.

Description

Related Catalog

Research Areas >> Cancer

Signaling Pathways >> Antibody-drug Conjugate >> Drug-Linker Conjugates for ADC

References

[1]. Earl F Albone, et al. Eribulin-based antibody-drug conjugates and methods of use. US20170252458A1.

[2]. Towle MJ, et al. Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res. 2011 Jan 15;71(2):496-505.